Francisco M. Mouro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Francisco M. Mouro has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Ana Maria Sebastião
Instituto de Farmacologia e Neurociências, Faculdade de Medicina Universidade de Lisboa Lisboa Portugal
6 shared publications - João Fonseca-Gomes
Faculdade de Medicina da Universidade de Lisboa
3 shared publications - Maria José Diógenes
Centro Cardiovascular da Universidade de Lisboa (CCUL@RISE); Medicine.Ulisboa for health, clinical research and Innovation (MUHCRI); Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal; GIMM - Gulbenkian Institute for Molecular Medicine, Lisbon, Portugal
3 shared publications - Sara R. Tanqueiro
Faculdade de Medicina da Universidade de Lisboa
3 shared publications - Sara Xapelli
Instituto de Farmacologia e Neurociências, Faculdade de Medicina Universidade de Lisboa Lisbon Portugal
3 shared publications Catarina B. Ferreira
Faculdade de Medicina da Universidade de Lisboa
2 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (18) , 5440-5457
Cannabinoid and adenosine A 2A receptor crosstalk regulates postnatal and adult hippocampal neurogenesis
Background and purpose: Adult neurogenesis is a tightly regulated process affected by both cannabinoid receptors (CB 1 and CB 2 ) and adenosine 2A (A 2A ) receptors, both of which modulate neural progenitor cell activity. While emerging evidence suggests an interaction between these neuromodulatory systems, the extent and mechanism of their interplay in regulating neurogenesis remain unclear. Experimental approach: Using a combination of in vivo and in vitro approaches together with pharmacological and receptor/binding assays, we investigated the crosstalk between A 2A and CB receptors in regulating hippocampal neurogenesis. Key results: In vivo administration of WIN55212‐2, a non‐selective cannabinoid receptor agonist, increased hippocampal cell proliferation and immature neuron formation, an effect abolished by istradefylline, a selective A 2A receptor antagonist. In vitro , activation of CB 2 or A 2A receptors promoted self‐renewing divisions of hippocampal‐derived neural progenitor cells. A 2A receptor antagonism impaired CB 2 receptor‐mediated effects, whereas CB 1 /CB 2 antagonism blocked A 2A ‐mediated effects. Co‐activation of CB 1 or CB 2 receptors with A 2A receptors promoted a significant increase in cell proliferation. Notably, the proneurogenic effects mediated by CB 1 or CB 2 receptor agonists were blocked by A 2A receptor antagonism, while A 2A receptor‐mediated actions on neuronal differentiation were blocked by CB 1 or CB 2 receptor antagonists. Finally, receptor‐binding assays showed that A 2A and CB 1 receptors form heteromers in the mouse hippocampus, suggesting that their functional interaction may involve direct receptor‐receptor crosstalk. Conclusions and implications: Taken together, these findings suggest a crosstalk between the adenosinergic and cannabinergic systems responsible for regulating hippocampal progenitor dynamics. The identification of CB 1 –A 2A receptor heteromerization provides new insights into the molecular basis of neurogenic modulation and highlights a promising avenue for the development of novel proneurogenic therapeutic strategies.
- 22 June 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (18) , 5440-5457
Open AccessCannabinoid and adenosine A 2A receptor crosstalk regulates postnatal and adult hippocampal neurogenesis
Background and purpose: Adult neurogenesis is a tightly regulated process affected by both cannabinoid receptors (CB 1 and CB 2 ) and adenosine 2A (A 2A ) receptors, both of which modulate neural progenitor cell activity. While emerging evidence suggests an interaction between these neuromodulatory systems, the extent and mechanism of their interplay in regulating neurogenesis remain unclear. Experimental approach: Using a combination of in vivo and in vitro approaches together with pharmacological and receptor/binding assays, we investigated the crosstalk between A 2A and CB receptors in regulating hippocampal neurogenesis. Key results: In vivo administration of WIN55212‐2, a non‐selective cannabinoid receptor agonist, increased hippocampal cell proliferation and immature neuron formation, an effect abolished by istradefylline, a selective A 2A receptor antagonist. In vitro , activation of CB 2 or A 2A receptors promoted self‐renewing divisions of hippocampal‐derived neural progenitor cells. A 2A receptor antagonism impaired CB 2 receptor‐mediated effects, whereas CB 1 /CB 2 antagonism blocked A 2A ‐mediated effects. Co‐activation of CB 1 or CB 2 receptors with A 2A receptors promoted a significant increase in cell proliferation. Notably, the proneurogenic effects mediated by CB 1 or CB 2 receptor agonists were blocked by A 2A receptor antagonism, while A 2A receptor‐mediated actions on neuronal differentiation were blocked by CB 1 or CB 2 receptor antagonists. Finally, receptor‐binding assays showed that A 2A and CB 1 receptors form heteromers in the mouse hippocampus, suggesting that their functional interaction may involve direct receptor‐receptor crosstalk. Conclusions and implications: Taken together, these findings suggest a crosstalk between the adenosinergic and cannabinergic systems responsible for regulating hippocampal progenitor dynamics. The identification of CB 1 –A 2A receptor heteromerization provides new insights into the molecular basis of neurogenic modulation and highlights a promising avenue for the development of novel proneurogenic therapeutic strategies.
- Open Access
Cleavage of the TrkB-FL Receptor During Epileptogenesis: Insights from a Kainic Acid-Induced Model of Epilepsy and Human Samples
A bstract: Brain-derived neurotrophic factor (BDNF) is essential for neuronal survival, differentiation, and plasticity. In epilepsy, BDNF exhibits a dual role, exerting both antiepileptic and pro-epileptic effects. The cleavage of its main receptor, full-length tropomyosin-related kinase B (TrkB-FL), was suggested to occur in status epilepticus (SE) in vitro. Moreover, under excitotoxic conditions, TrkB-FL was found to be cleaved, resulting in the formation of a new intracellular fragment, TrkB-ICD. Thus, we hypothesized that TrkB-FL cleavage and TrkB-ICD formation could represent an uncovered mechanism in epilepsy. We used a rat model of mesial temporal lobe epilepsy (mTLE) induced by kainic acid (KA) to investigate TrkB-FL cleavage and TrkB-ICD formation during SE and established epilepsy (EE). Animals treated with 10 mg/kg of KA exhibited TrkB-FL cleavage during SE, with hippocampal levels of TrkB-FL and TrkB-ICD correlating with seizure severity. Notably, TrkB-FL cleavage and TrkB-ICD formation were also detected in animals with EE, which exhibited spontaneous recurrent convulsive seizures, neuronal death, mossy fiber sprouting, and long-term memory impairment. Importantly, hippocampal samples from patients with refractory epilepsy also showed TrkB-FL cleavage with increased TrkB-ICD levels. Additionally, overexpression of TrkB-ICD in the hippocampus of healthy rodents resulted in long-term memory impairment. Our findings suggest that TrkB-FL cleavage and the subsequent TrkB-ICD production occur throughout epileptogenesis, with the extent of cleavage correlating positively with seizure occurrence. Moreover, we found that TrkB-ICD impairs memory. This work uncovers a novel mechanism in epileptogenesis that could serve as a potential therapeutic target in mTLE, with implications for preserving cognitive function.
Open AccessCleavage of the TrkB-FL Receptor During Epileptogenesis: Insights from a Kainic Acid-Induced Model of Epilepsy and Human Samples
A bstract: Brain-derived neurotrophic factor (BDNF) is essential for neuronal survival, differentiation, and plasticity. In epilepsy, BDNF exhibits a dual role, exerting both antiepileptic and pro-epileptic effects. The cleavage of its main receptor, full-length tropomyosin-related kinase B (TrkB-FL), was suggested to occur in status epilepticus (SE) in vitro. Moreover, under excitotoxic conditions, TrkB-FL was found to be cleaved, resulting in the formation of a new intracellular fragment, TrkB-ICD. Thus, we hypothesized that TrkB-FL cleavage and TrkB-ICD formation could represent an uncovered mechanism in epilepsy. We used a rat model of mesial temporal lobe epilepsy (mTLE) induced by kainic acid (KA) to investigate TrkB-FL cleavage and TrkB-ICD formation during SE and established epilepsy (EE). Animals treated with 10 mg/kg of KA exhibited TrkB-FL cleavage during SE, with hippocampal levels of TrkB-FL and TrkB-ICD correlating with seizure severity. Notably, TrkB-FL cleavage and TrkB-ICD formation were also detected in animals with EE, which exhibited spontaneous recurrent convulsive seizures, neuronal death, mossy fiber sprouting, and long-term memory impairment. Importantly, hippocampal samples from patients with refractory epilepsy also showed TrkB-FL cleavage with increased TrkB-ICD levels. Additionally, overexpression of TrkB-ICD in the hippocampus of healthy rodents resulted in long-term memory impairment. Our findings suggest that TrkB-FL cleavage and the subsequent TrkB-ICD production occur throughout epileptogenesis, with the extent of cleavage correlating positively with seizure occurrence. Moreover, we found that TrkB-ICD impairs memory. This work uncovers a novel mechanism in epileptogenesis that could serve as a potential therapeutic target in mTLE, with implications for preserving cognitive function.
- 1 December 2020
- Published by Elsevier in Pharmacological Research
- Vol. 162, 105281
Challenges of BDNF-based therapies: From common to rare diseases
- 1 December 2020
- Published by Elsevier in Pharmacological Research
- Vol. 162, 105281
Challenges of BDNF-based therapies: From common to rare diseases
- Open Access
- 1 November 2020
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 8609-8621
In vivo Bio-Distribution and Toxicity Evaluation of Polymeric and Lipid-Based Nanoparticles: A Potential Approach for Chronic Diseases Treatment
Introduction: Nanoparticles (NPs), as drug delivery systems, appear to be a promising tool for prolonged therapeutic strategies as they allow a controlled drug release over time. However, most of the studies found in the literature simply contemplate the use of a single or low number of dosages with low NPs concentrations. In the context of chronic diseases, like Alzheimer’s disease, cancer or human immunodeficiency virus (HIV), where the therapeutic scheme is also chronic, studies with numerous repeated dosages are often neglected. Methods: We screened different NPs, polymeric and lipid-based, in a repeated-dose toxicity study, to evaluate the safety and tissue distribution of promising nanocarriers to be used in the treatment of long-lasting diseases. Results: After administrating 24 high concentrated doses of the selected NPs intraperitoneally (i.p.) (3 times a week for 2 months), animals have presented NPs accumulation in different tissues. However, neither toxicity, bodyweight changes nor clinical signs of disease were observed. Discussion: This work demonstrates no general adverse effects upon the studied NPs repeated-dose exposure, indicating the most promising NPs to be used in the different therapeutic circumstances, which may be useful in chronic diseases treatment.
- 1 November 2020
- Published by Taylor & Francis in International Journal of Nanomedicine
- Vol. ume 15, 8609-8621
Open AccessIn vivo Bio-Distribution and Toxicity Evaluation of Polymeric and Lipid-Based Nanoparticles: A Potential Approach for Chronic Diseases Treatment
Introduction: Nanoparticles (NPs), as drug delivery systems, appear to be a promising tool for prolonged therapeutic strategies as they allow a controlled drug release over time. However, most of the studies found in the literature simply contemplate the use of a single or low number of dosages with low NPs concentrations. In the context of chronic diseases, like Alzheimer’s disease, cancer or human immunodeficiency virus (HIV), where the therapeutic scheme is also chronic, studies with numerous repeated dosages are often neglected. Methods: We screened different NPs, polymeric and lipid-based, in a repeated-dose toxicity study, to evaluate the safety and tissue distribution of promising nanocarriers to be used in the treatment of long-lasting diseases. Results: After administrating 24 high concentrated doses of the selected NPs intraperitoneally (i.p.) (3 times a week for 2 months), animals have presented NPs accumulation in different tissues. However, neither toxicity, bodyweight changes nor clinical signs of disease were observed. Discussion: This work demonstrates no general adverse effects upon the studied NPs repeated-dose exposure, indicating the most promising NPs to be used in the different therapeutic circumstances, which may be useful in chronic diseases treatment.
- Open Access
- 16 September 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (23) , 4386-4397
Adenosine A2Areceptors facilitate synaptic NMDA currents in CA1 pyramidal neurons
Background and Purpose: NMDA receptors play a key role in both synaptic plasticity and neurodegeneration. Adenosine is an endogenous neuromodulator and through membrane receptors of the A2Asubtype can influence both synaptic plasticity and neuronal death. The present work was designed to evaluate the influence of adenosine A2Areceptors upon NMDA receptor activity in CA1 hippocampal neurons. We discriminated between modulation of synaptic versus extrasynaptic receptors, since extrasynaptic NMDA receptors are mostly associated with neurodegeneration while synaptic NMDA receptors are linked to plasticity phenomena.Experimental Approach: Whole‐cell patch‐clamp recordings were obtained to evaluate NMDA receptor actions on CA1 pyramidal neurons of young adult (5–10 weeks) male Wistar rat hippocampus.Key Results: Activation of A2Areceptors with CGS 21680 (30 nM) consistently facilitated chemically‐evoked NMDA receptor‐currents (NMDA‐PSCs) and afferent‐evoked NMDA‐currents (NMDA‐EPSCs), an action prevented by an A2Areceptor antagonist (SCH58261, 100 nM) and a PKA inhibitor, H‐89 (1 μM). These actions did not reflect facilitation in glutamate release since there was no change in NMDA‐EPSCs paired pulse ratio. A2Areceptor actions were lost in the presence of an open‐channel NMDA receptor blocker, MK‐801 (10 μM), but persisted in the presence of memantine, at a concentration (10 μM) known to preferentially block extrasynaptic NMDA receptors.Conclusion and Implications: These results show that A2Areceptors exert a positive postsynaptic modulatory effect over synaptic, but not extrasynaptic, NMDA receptors in CA1 neurons and, therefore, under non‐pathological conditions may contribute to shift the dual role of NMDA receptors towards enhancement of synaptic plasticity.
- 16 September 2018
- Published by Wiley in British Journal of Pharmacology
- Vol. 175 (23) , 4386-4397
Open AccessAdenosine A2Areceptors facilitate synaptic NMDA currents in CA1 pyramidal neurons
Background and Purpose: NMDA receptors play a key role in both synaptic plasticity and neurodegeneration. Adenosine is an endogenous neuromodulator and through membrane receptors of the A2Asubtype can influence both synaptic plasticity and neuronal death. The present work was designed to evaluate the influence of adenosine A2Areceptors upon NMDA receptor activity in CA1 hippocampal neurons. We discriminated between modulation of synaptic versus extrasynaptic receptors, since extrasynaptic NMDA receptors are mostly associated with neurodegeneration while synaptic NMDA receptors are linked to plasticity phenomena.Experimental Approach: Whole‐cell patch‐clamp recordings were obtained to evaluate NMDA receptor actions on CA1 pyramidal neurons of young adult (5–10 weeks) male Wistar rat hippocampus.Key Results: Activation of A2Areceptors with CGS 21680 (30 nM) consistently facilitated chemically‐evoked NMDA receptor‐currents (NMDA‐PSCs) and afferent‐evoked NMDA‐currents (NMDA‐EPSCs), an action prevented by an A2Areceptor antagonist (SCH58261, 100 nM) and a PKA inhibitor, H‐89 (1 μM). These actions did not reflect facilitation in glutamate release since there was no change in NMDA‐EPSCs paired pulse ratio. A2Areceptor actions were lost in the presence of an open‐channel NMDA receptor blocker, MK‐801 (10 μM), but persisted in the presence of memantine, at a concentration (10 μM) known to preferentially block extrasynaptic NMDA receptors.Conclusion and Implications: These results show that A2Areceptors exert a positive postsynaptic modulatory effect over synaptic, but not extrasynaptic, NMDA receptors in CA1 neurons and, therefore, under non‐pathological conditions may contribute to shift the dual role of NMDA receptors towards enhancement of synaptic plasticity.
- Open Access
- 10 July 2018
- Published by Wiley in Journal of Neurochemistry
- Vol. 147 (1) , 71-83
Chronic, intermittent treatment with a cannabinoid receptor agonist impairs recognition memory and brain network functional connectivity
Elucidating how cannabinoids affect brain function is instrumental for the development of therapeutic tools aiming to mitigate ‘on target’ side effects of cannabinoid‐based therapies. A single treatment with the cannabinoid receptor agonist, WIN 55,212‐2, disrupts recognition memory in mice. Here, we evaluate how prolonged, intermittent (30 days) exposure to WIN 55,212‐2 (1 mg/kg) alters recognition memory and impacts on brain metabolism and functional connectivity. We show that chronic, intermittent treatment with WIN 55,212‐2 disrupts recognition memory (Novel Object Recognition Test) without affecting locomotion and anxiety‐like behaviour (Open Field and Elevated Plus Maze). Through 14C‐2‐deoxyglucose functional brain imaging we show that chronic, intermittent WIN 55,212‐2 exposure induces hypometabolism in the hippocampal dorsal subiculum and in the mediodorsal nucleus of the thalamus, two brain regions directly involved in recognition memory. In addition, WIN 55,212‐2 exposure induces hypometabolism in the habenula with a contrasting hypermetabolism in the globus pallidus. Through the application of the Partial Least Squares Regression (PLSR) algorithm to the brain imaging data, we observed that prolonged WIN 55,212‐2 administration alters functional connectivity in brain networks that underlie recognition memory, including that between the hippocampus and prefrontal cortex, the thalamus and prefrontal cortex, and between the hippocampus and the perirhinal cortex. In addition, our results support disturbed lateral habenula and serotonin system functional connectivity following WIN 55,212‐2 exposure. Overall, this study provides new insight into the functional mechanisms underlying the impact of chronic cannabinoid exposure on memory and highlights the serotonin system as a particularly vulnerable target. image
- 10 July 2018
- Published by Wiley in Journal of Neurochemistry
- Vol. 147 (1) , 71-83
Open AccessChronic, intermittent treatment with a cannabinoid receptor agonist impairs recognition memory and brain network functional connectivity
Elucidating how cannabinoids affect brain function is instrumental for the development of therapeutic tools aiming to mitigate ‘on target’ side effects of cannabinoid‐based therapies. A single treatment with the cannabinoid receptor agonist, WIN 55,212‐2, disrupts recognition memory in mice. Here, we evaluate how prolonged, intermittent (30 days) exposure to WIN 55,212‐2 (1 mg/kg) alters recognition memory and impacts on brain metabolism and functional connectivity. We show that chronic, intermittent treatment with WIN 55,212‐2 disrupts recognition memory (Novel Object Recognition Test) without affecting locomotion and anxiety‐like behaviour (Open Field and Elevated Plus Maze). Through 14C‐2‐deoxyglucose functional brain imaging we show that chronic, intermittent WIN 55,212‐2 exposure induces hypometabolism in the hippocampal dorsal subiculum and in the mediodorsal nucleus of the thalamus, two brain regions directly involved in recognition memory. In addition, WIN 55,212‐2 exposure induces hypometabolism in the habenula with a contrasting hypermetabolism in the globus pallidus. Through the application of the Partial Least Squares Regression (PLSR) algorithm to the brain imaging data, we observed that prolonged WIN 55,212‐2 administration alters functional connectivity in brain networks that underlie recognition memory, including that between the hippocampus and prefrontal cortex, the thalamus and prefrontal cortex, and between the hippocampus and the perirhinal cortex. In addition, our results support disturbed lateral habenula and serotonin system functional connectivity following WIN 55,212‐2 exposure. Overall, this study provides new insight into the functional mechanisms underlying the impact of chronic cannabinoid exposure on memory and highlights the serotonin system as a particularly vulnerable target. image